A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression

• ClinicalTrials.gov Identifier: NCT00718770
• Recruitment Status: Completed
• First Posted: July 21, 2008
• Results First Posted: January 17, 2014
• Last Update Posted: January 17, 2014
• Sponsor: University of Colorado, Denver
• Collaborators: American Cancer Society, Inc.; Eisai Inc.
• Information provided by (Responsible Party): University of Colorado, Denver

Study Description

Brief Summary:

This study plans to learn more about a drug called bexarotene for the treatment of advanced thyroid cancer. Subjects are asked to be in this study because they have thyroid cancer that will not respond to radioactive iodine therapy and shows signs of aggressive behavior.

Bexarotene has been FDA approved for the treatment of a type of skin cancer called cutaneous T-cell lymphoma, but has not been FDA approved for this use. Bexarotene is investigational in the treatment of thyroid cancer.

The purpose of this research study is to test how well the study drug works in humans. The study doctors want to know if:

1. The subjects thyroid cancer gets smaller while you are taking the study drug.
2. The subjects thyroid cancer takes up radioactive iodine better after treatment with the study drug than before treatment.

Condition or disease	Intervention/treatment	Phase
Thyroid Cancer	Drug: Bexarotene	Early Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Rexinoid Therapy for Poorly Differentiated Thyroid Cancer: A Pilot Clinical Trial and Correlation to Retinoid and PPARy Receptor Expression
• Study Start Date: November 2008
• Actual Primary Completion Date: January 2013
• Actual Study Completion Date: February 2013

Arms and Interventions

Arm	Intervention/treatment
Experimental: Bexarotene; Open label - all patients receive intervention	Drug: Bexarotene; Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.; Other Name: LGD-1069

Outcome Measures

Primary Outcome Measures :

1. Change in Tumor Size [ Time Frame: 1 year ]
   To assess the tumor response of recurrent or metastatic radioiodine resistant thyroid cancer to bexarotene therapy using standard RECIST criteria

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subject must have a histologically/cytologically confirmed diagnosis of papillary, follicular, or anaplastic thyroid cancer (any follicular cell derived thyroid cancer).
• Subjects must have evidence of follicular cell-derived thyroid cancer progression. In patients with anatomically stable disease, PET positive lesions will also be eligible given the poor prognostic risk for PET positive thyroid cancer.
• Subjects must not be eligible for surgical resection.
• Subjects must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
• Subjects must have laboratory values that fall within certain ranges.
• Subjects must be age 18 years or older.
• Subjects must provide written informed consent prior to any study procedures being performed.
• Females of childbearing potential must have a negative pregnancy test prior to enrollment.
• All eligible subjects must be willing to use adequate contraception throughout the duration of the study.
• Subjects must be willing to submit a primary tumor tissue sample for immunohistochemical analysis.
• Subjects have the option of providing one additional test tube of blood taken at baseline, 6 months and 1 year for banking of plasma for potential future studies (no genetic testing will be conducted). The current planned analysis is for the assessment of a potential peripheral marker for rexinoid responsive cancer - leukemia inhibitory factor (LIF)

Exclusion Criteria:

• Subjects with a known history of hyperlipidemia refractory to treatment.
• Subjects with a known history of hypertriglyceridemia refractory to treatment.
• Subjects with leukopenia below the reference range for the University of Colorado Hospital (UCH) laboratory.
• Subjects, who are pregnant, have a desire to become pregnant or are breastfeeding.
• Subjects who are unwilling or unable to comply with study medication administration, or study guidelines, as determined by the investigator.
• Subjects with any prior history of malignancy with the exception of adequately treated basal cell skin cancer, in situ cervical cancer or other cancer for which the subject has been disease free for 3 years or more.
• Subjects without radiographically assessable disease

Contacts and Locations

Locations

United States, Colorado

University of Colorado Cancer Center

Aurora, Colorado, United States, 80045

Sponsors and Collaborators

University of Colorado, Denver

American Cancer Society, Inc.

Eisai Inc.

Investigators

• Principal Investigator: Joshua Klopper, MD; University of Colorado, Denver

More Information

• Responsible Party: University of Colorado, Denver
• ClinicalTrials.gov Identifier: NCT00718770
• Other Study ID Numbers: 07-0727.cc
• First Posted: July 21, 2008
• Results First Posted: January 17, 2014
• Last Update Posted: January 17, 2014
• Last Verified: December 2013

Keywords provided by University of Colorado, Denver:

Not respond; Radioactive iodine; Therapy; Shows signs; Aggressive behavior

Additional relevant MeSH terms:

Thyroid Neoplasms; Thyroid Diseases; Endocrine System Diseases; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Bexarotene; Antineoplastic Agents